ArticleNAR cancer2025
DVFGCDR: a dual-view fusion graph neural network for cancer drug response prediction.
Article in NAR cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prediction of cancer drug responses (CDRs) holds considerable relevance for the guidance of patient-specific clinical treatments. However, the inherent cellular heterogeneity among cancers introduces substantial challenges to such predictions. This paper presents a novel molecular graph convolutional model, named DVFGCDR, developed for predicting CDRs. This innovative model amalgamates both 2D chemical and 3D geometric drug properties to derive a more representative drug embedding. It also includes the capacity to integrate gene expression data from single-cell and bulk RNA sequencing data associated with hundreds of cancer cell lines, thereby enhancing the accuracy of drug response predictions. Experimental comparisons highlight the superior performance of the DVFGCDR model in CDR classification and regression tasks, achieving a Pearson score of 0.959, surpassing current state-of-the-art models. This superiority underscores the model's powerful predictive capability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.